Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-12 Gene Medicine in SCCHN
NCT00004070Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 1999
- Primary completion
- Nov 2000
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of interleukin-12 plasmid in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Dana-Farber Cancer Institute. Started Jul 1999; status: completed.
02
Drugs
interleukin-12 plasmid
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00004070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004070.